Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.56 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.56 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.56 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.52 |
| ▸ | EGFR | P00533 | 3/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.47 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | PRKACA | P17612 | 1/20 | 0.47 |
| ▸ | LTK | P29376 | 1/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11821044 | 0.76 | PI4KA (0.56) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| SCHEMBL3075421 | 0.75 | ADORA2A (0.75) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| SCHEMBL637552 | 0.71 | PI4KA (0.56) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| SCHEMBL2010225 | 0.71 | PI4KA (0.56) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| SCHEMBL18087089 | 0.71 | PI4KA (0.56) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| SCHEMBL25620 | 0.71 | PDE4A (1.00) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| SCHEMBL276986 | 0.71 | PI4KA (0.56) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| SCHEMBL3951708 | 0.71 | PI4KA (0.56) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| 4-Aminoquinazoline SCHEMBL142513 | 0.71 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| SCHEMBL12559893 | 0.71 | PI4KA (0.56) | PI4KAPI4K2BPI4K2API4KBPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3542801-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAP-RELATED DISEASES | Boehringer Ingelheim International GmbH (DE) | 2019-09-25 | — | — | EP | claimed |
| US-20160136180-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2016-05-19 | — | — | US | claimed |
| US-20110112069-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-12 | — | — | US | claimed |
| EP-1532149-B9 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PRODUCTION THEREOF AND THE USE OF THE SAME AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2011-04-20 | — | — | EP | claimed |
| CN-101784278-A | Purin derivatives for use in the treatment of FAB-related diseases | BOEHRINGER INGELHEIM INT | 2010-07-21 | — | — | CN | claimed |
| EP-2190434-A2 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | Boehringer Ingelheim International GmbH (DE) | 2010-06-02 | — | — | EP | claimed |
| EP-1532149-B1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PRODUCTION THEREOF AND THE USE OF THE SAME AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-12-30 | — | — | EP | claimed |
| EP-2091929-A1 | AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS | The European Molecular Biology Laboratory (DE) | 2009-08-26 | — | — | EP | claimed |
| WO-2009024542-A2 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-26 | — | — | WO | claimed |
| US-20080255159-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2008-10-16 | — | — | US | claimed |
| US-20080249089-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2008-10-09 | — | — | US | claimed |
| WO-2007107352-A1 | AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS | THE EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2007-09-27 | — | — | WO | claimed |
| EP-1362048-B1 | TRIAZOLO COMPOUNDS AS MMP INHIBITORS | WARNER LAMBERT CO (US) | 2005-05-04 | — | — | EP | claimed |
| US-20040097510-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-20 | — | — | US | claimed |
| EP-1362048-A1 | TRIAZOLO COMPOUNDS AS MMP INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | claimed |
| WO-2002064595-A1 | TRIAZOLO COMPOUNDS AS MMP INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | claimed |
| CN-1352644-A | I-amino triazolo [4,3-alpha] quinazoline -5-ones and/or -5-thiones inhibiting phosphodiesterase IV | WARNER LAMBERT CO (US) | 2002-06-05 | — | — | CN | claimed |
| EP-3542801-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAP-RELATED DISEASES | Boehringer Ingelheim International GmbH (DE) | 2019-09-25 | — | — | EP | disclosed |
| CN-1352644-A | I-amino triazolo [4,3-alpha] quinazoline -5-ones and/or -5-thiones inhibiting phosphodiesterase IV | WARNER LAMBERT CO (US) | 2002-06-05 | — | — | CN | disclosed |
| CN-1348763-A | Medicine composite for preventing or treaitng diseases relating to IL-12 over growth | WARNER LAMBERT CO (US) | 2002-05-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255159-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP3 | PI4KA 1546/4885PI4K2B 2905/4885PI4K2A 3134/4885 |
| US-20080249089-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP3 | PI4KA 1546/4885PI4K2B 2905/4885PI4K2A 3134/4885 |
| US-20160136180-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | PNP, ENTPD5, NUDT14 | PI4KA 1929/4885PI4K2B 1824/4885PI4K2A 1691/4885 |
| US-20110112069-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | PNP, PURB, NUDT14 | PI4KA 1903/4885PI4K2B 1621/4885PI4K2A 1649/4885 |
| US-20040097510-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | DPP8, DPP4, DPP3 | PI4KA 918/4885PI4K2B 1600/4885PI4K2A 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.